Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours

European Journal of Cancer

Volumn 42, Issue 12, 2006, Pages 1768-1774

  de Jonge, M J A ^a   Dumez, H ^b   Verweij, J ^a   Yarkoni, S ^c   Snyder, D ^c   Lacombe, D ^d   Marreaud S ^d   Yamaguchi, T ^d   Punt, C J A ^e   van Oosterom, A ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c Medica L P   (Israel)

^d EORTC DATA CENTER   (Belgium)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anti angiogenetic; Halofuginone; Phase I; Tempostatin

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; HALOFUGINONE; QUINAZOLINONE DERIVATIVE; TEMPOSTATIN;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BRAIN METASTASIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTOPENIA; HEMATOMA; HUMAN; HYPONATREMIA; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; MELANOMA; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECTUM CANCER; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SARCOMA; SOLID TUMOR; STOMACH HEMORRHAGE; STOMACH ULCER; THROMBOCYTOPENIA; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; FATIGUE; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NAUSEA; NEOPLASMS; PIPERIDINES; QUINAZOLINES; QUINAZOLINONES; VOMITING;

EID: 33746584381     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.12.027     Document Type: Article

References (18)

1. Ramirez F., and Rifkin D.B. Cell signaling events: a view from the matrix. Matrix Biol 22 (2003) 101-107
2. Folz S.D., Lee B.L., Nowakowski L.H., and Conder G.A. Anticoccidial evaluation of halofuginone, lasalocid, maduramicin, monensin and salinomycin. Vet Parasitol 28 (1988) 1-9
3. Halevy O., Nagler A., Levi-Schaffer F., Genina O., and Pines M. Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients: effect of halofuginone. Biochem Pharmacol 52 (1996) 1057-1063
4. Granot I., Halevy O., Hurwitz S., and Pines M. Halofuginone: an inhibitor of collagen type I synthesis. Biochim Biophys Acta 1156 (1993) 107-112
5. Pines M., Knopov V., Genina O., Lavelin I., and Nagler A. Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis. J Hepatol 27 (1997) 391-398
6. Pines M., and Nagler A. Halofuginone: a novel antifibrotic therapy. Gen Pharmacol 30 (1998) 445-450
7. Elkin M., Miao H.-Q., Nagler A., et al. Halofuginone: a potent inhibitor of critical steps in angiogenesis progression. FASEB J 14 (2000) 2477-2485
8. McGaha T.L., Phelps R.G., Spiera H., and Bona C. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-β-mediated Smad3 activation in fibroblasts. J Invest Dermatol 118 (2002) 461-470
9. Nagler A., Miao H.Q., Aingorn H., et al. Inhibition of collagen synthesis, smooth muscle cell proliferation, and injury-induced intimal hyperplasia by halofuginone. Arterioscler Thromb Vasc Biol 17 (1997) 194-202
10. Elkin M., Reich R., Nagler A., et al. Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone. Clin Cancer Res 5 (1999) 1982-1988
11. Elkin M., Ariel I., Miao H.-Q., et al. Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone. Cancer Res 59 (1999) 4111-4118
12. Abramovitch R., Itzik A., Harel H., Nagler A., Vlodavsky I., and Siegal T. Halofuginone inhibits angiogenesis and growth in implanted metastatic rat brain tumor model - an MRI study. Neoplasia 6 (2004) 480-489
13. Nagler A., Ohana M., Shibolet O., et al. Suppression of hepatocellular carcinoma growth in mice by the alkaloid coccidiostat halofuginone. Eur J Cancer 40 (2004) 1397-1403
14. Gross D.J., Reibstein I., Weiss L., et al. Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo. Clin Cancer Res 9 (2003) 3788-3793
15. Gavish Z., Pinthus J.H., Barak V., et al. Growth inhibition of prostate cancer xenografts by halofuginone. Prostate 51 (2002) 73-83
16. Stecklair K.P., Hamburger D.R., Egorin M.J., Parise R.A., Covey J.M., and Eiseman J.L. Pharmacokinetics and tissue distribution of halofuginone (NSC 713205) in CD2F1 mice and fisher 344 rats. Cancer Chemother Pharmacol 48 (2001) 375-382
17. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment of solid tumours. J Natl Cancer Instit 92 (2000) 205-216
18. Mick R., Crowley J., Carroll R., et al. Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint. Contr Clin Trials 21 (2000) 343-359